Clinical Trials Directory

Trials / Completed

CompletedNCT07317713

A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022

Status
Completed
Phase
Study type
Observational
Enrollment
93,481 (actual)
Sponsor
Suez Canal University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature.

Detailed description

Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature. This is a retrospective cohort study based on the Surveillance, Epidemiology, and End Results (SEER) database using SEER\*Stat software covering approximately 28% of the U.S. The inclusion criteria involved all patients with primary malignant GI carcinoid tumor diagnosed between 2000 and 2021 with sequence number 0 or 1. Sequence 0 indicated the patient had only one cancer record while sequence 1 indicated the patient may had developed many cancer records following the first one. In addition, the tumors were restricted to malignant behavior codes (ICD-O-3 Code 3). We used SEER\*Stat software (version 9.0.42.0) to conduct data extraction and statistical analysis. We used the MP-SIR session to calculate the SMR as Observed/Expected (O/E) with a 95% confidence interval (CI) and the excess risk (ER) was per 10,000. Statistical significance was achieved at 0.05. With further analysis, we compared cancer as a cause of death (COD) to other non-cancer COD across different time intervals and primary sites among GI carcinoid tumour.

Conditions

Timeline

Start date
2000-12-01
Primary completion
2022-12-30
Completion
2022-12-30
First posted
2026-01-05
Last updated
2026-01-05

Source: ClinicalTrials.gov record NCT07317713. Inclusion in this directory is not an endorsement.